TY  - JOUR
T1  - CYp2c19 genotype and cardiovascular events—reply
AU  - Holmes MV, Hingorani AD, Casas JP
Y1  - 2012/04/11
N1  - 10.1001/jama.2012.446
JO  - JAMA
SP  - 1482
EP  - 1485
VL  - 307
IS  - 14
N2  - 
In Reply:  We considered all included trials to be within the remit of our systematic review, including those involving patients receiving clopidogrel for indications other than PCI.1- 3 However, based on the letters from Dr Shuldiner and Dr Mega and their colleagues, we excluded these studies, which yielded a summary relative risk (RR) of 1.22 (95% CI, 1.11-1.33) for the association of CYP2C19 genotype with cardiovascular disease (CVD) events. The addition of the 3 studies alluded to by Mega et al, excluded by us because they focused solely on stent thrombosis, yielded a summary RR of 1.21 (95% CI, 1.12-1.30) for CVD events. These modest effect estimates also remain affected by small-study bias.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.446
UR  - http://dx.doi.org/10.1001/jama.2012.446
ER  -